NOVABIOTICS LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Azets Audit Services

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“After making appropriate enquiries and reviewing cash flow forecasts, the directors have formed a judgment at the time of approving the financial statements that the Group has access to adequate resources to continue in operational existence for at least twelve months. For this reason, the directors believe it remains appropriate to continue to prepare the financial statements on a going concern basis.”

Group structure

1. NOVABIOTICS LIMITED · parent
   1. Novabiotics Incorporated 100% · US
   2. Novabiotics Limited 100% · Ireland
   3. Novabiotics Consumer Health 99% · United Kingdom · Consumer health products

Significant events

• “Following the year end on 28 April 2025, a Licence Agreement for Tinexyl® with Brand Creations International Ltd was executed.”
• “Tinexyl® has been launched as a B2B product in the UK as Tinexyl® PRO (for podiatrists and foot health practitioners) and through our worldwide distribution partner, digital test marketing has begun as a D2C product for Tinexyl® Nail ER in the US.”
• “Exposure to the 2025 imposed US tariffs has been minimised as the US market will be served by a US manufacturer and the UK and other markets by a UK manufacture.”
• “Novabiotics consumer health was newly incorporated with share capital of £100 on 28 February 2024 with Novabiotics Limited as the sole shareholder.”
• “Since the financial year end 29 November 2024, an additional £375k has been subscribed in convertible loan notes.”
• “On 28 April 2025, a Licence Agreement for Tinexyl® with Brand Creations International Ltd was executed granting them the rights to manufacture, market and sell Tinexyl® across direct-to-consumer markets worldwide except the Caribbean, where another distribution partner already has rights.”
• “In July 2025, an agreement was reached with a supplier to write off £115,839 of disputed invoiced amounts.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -40.3%

  £241,383 → £144,118

• Net assets

  -43.5%

  £357,143 → £201,778

• Employees

  -7.7%

  13 → 12

• Operating profit

  +99.2%

  -£1,469,492 → -£11,601

• Profit before tax

  +68.2%

  -£2,045,225 → -£650,041

• Wages

  +23.5%

  £296,548 → £366,257

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers